Education
About Us
Working with TipRanks
Follow Us
Viracta Therapeutics, Inc. (VIRX)
:VIRX
VIRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.58
Previous CloseN/A
Volume1.67M
Average Volume (3M)148.38K
Market Cap
$437.19K
Enterprise Value$43.56M
Total Cash (Recent Filing)$21.13M
Total Debt (Recent Filing)$16.91M
Price to Earnings (P/E)―
Beta-0.47
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding39,744,220
10 Day Avg. Volume179,484
30 Day Avg. Volume148,379
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.90
Price to Sales (P/S)0.00
P/FCF Ratio-1.55
Enterprise Value/Market Cap99.63
Enterprise Value/Revenue14.76
Enterprise Value/Gross Profit106.50
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$0.25Price Target Upside2400.00% Upside
Rating ConsensusHold
Number of Analyst Covering0
Viracta Therapeutics News
PremiumPre-Earnings
Is VIRX a Buy, Before Earnings?
PremiumCompany Announcements
Viracta Therapeutics Announces Wind-Down and Leadership Changes
PremiumCompany Announcements
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure
Ownership Overview
2.48% Insiders
<0.01% Mutual Funds
0.27% Other Institutional Investors
97.25% Public Companies and Individual Investors
VIRX FAQ
What was Viracta Therapeutics, Inc.’s price range in the past 12 months?
Viracta Therapeutics, Inc. lowest stock price was <$0.01 and its highest was $0.58 in the past 12 months.
What is Viracta Therapeutics, Inc.’s market cap?
Viracta Therapeutics, Inc.’s market cap is $437.19K.
When is Viracta Therapeutics, Inc.’s upcoming earnings report date?
Viracta Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2025 which is in 22 days.
How were Viracta Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Viracta Therapeutics, Inc. overvalued?
According to Wall Street analysts Viracta Therapeutics, Inc.’s price is currently Undervalued.
Does Viracta Therapeutics, Inc. pay dividends?
Viracta Therapeutics, Inc. does not currently pay dividends.
What is Viracta Therapeutics, Inc.’s EPS estimate?
Viracta Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viracta Therapeutics, Inc. have?
Viracta Therapeutics, Inc. has 39,744,220 shares outstanding.
What happened to Viracta Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Viracta Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VIRX
Company Description
Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc. (VIRX) is a precision oncology company focused on developing targeted therapies for virus-associated cancers. The company's core product pipeline is centered around its proprietary drug candidates that are designed to selectively target and inhibit the viral proteins associated with certain cancer types, thereby enhancing the effectiveness of cancer treatment. Viracta's lead clinical program is aimed at treating Epstein-Barr virus (EBV)-associated malignancies, leveraging its novel approach to provide more effective treatment options for patients.